Evidence map›Paper›PMID 39840393›Full record

ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2025

Herbal Medicines as Complementary Therapy for Managing Complications in COVID-19 Patients with Diabetes Mellitus.

Syah Akbarul Adha, Nadiya Nurul Afifah, Irma Rahayu Latarissa, Ghina Nadhifah Iftinan, Arif Satria Wira Kusuma, Raden Maya Febriyanti, Melisa Intan Barliana, Keri Lestari

Abstract readReview
In one paragraph

Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Syah Akbarul AdhaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Nadiya Nurul AfifahDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0003-1817-436X
Irma Rahayu LatarissaDepartment of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0009-0009-6535-6685
Ghina Nadhifah IftinanMedication Therapy Adherence Clinic (MTAC), Universitas Padjadjaran, Sumedang, Indonesia.
Arif Satria Wira KusumaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Raden Maya FebriyantiDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-3437-3011
Melisa Intan BarlianaDepartment of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0003-0015-9604
Keri LestariCenter of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-2099-1062

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is recognized and classified as a group of conditions marked by persistent high blood glucose levels. It is also an inflammatory condition that may influence concurrent disease states, including Coronavirus Disease 2019 (COVID-19). Currently, no effective drug has been found to treat COVID-19, especially in DM patients. Many herbal medicines, such as the well-known

Indexed as

antidiabeticanti-inflammatoryCOVID-19diabetes mellitusherbal medicinesimmunomodulator

Identifiers

PMID39840393
PMCPMC11746946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.